SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 190.43-0.7%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Abuckatatime who wrote (28294)2/21/1999 9:49:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
Greg, Think of it this way. If you were a Japanese pharmaceutical looking to sell ONTAK for CTCL on label, with the potential for generating significant off label sales for other lymphomas, would you want oral and topical Targretin included, with their potential on CTCL) and off label sales (Breast Cancer)?

Look at LGND's deal with QLTIF to sell PHOTOFRIN in Canada. At the time it was just approved for superficial bladder cancer, but the agreement is for ALL indications, on or off label.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News